Search clinical trials for: Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC

Total 7 results

National Institute of Allergy and Infectious Diseases...
ViiV Healthcare; Mylan Inc.

Recruiting

Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

HIV-associated Tuberculosis

South Africa, Thailand
Kirby Institute

Active, not recruiting

Body Composition Sub-study of the D2EFT Trial

HIV Infections

Malaysia, Zimbabwe, India, South Africa, Thailand
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Rapid HIV Treatment Initiation, Access and Engagement in Care

Human Immunodeficiency Virus

United States
Fundacion SEIMC-GESIDA

Active, not recruiting

Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load (MAFALDA-R)

HIV Infections | Fatty Liver Disease

Spain
ANRS, Emerging Infectious Diseases
UNITAID; Institut de Recherche pour le Developpement

Completed

Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings (NAMSAL)

HIV-1 Infection

Cameroon
State University of New York at Buffalo
Gilead Sciences

Active, not recruiting

Bictegravir in the Elderly Living With HIV (BICEP)

HIV-1-infection

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Neuroblastoma | Ganglioneuroblastoma

United States, Canada, Puerto Rico

Search clinical trials for: Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations